May 04, 2023
The Federal Circuit declined to rethink a decision rejecting Gilead Sciences' and Astellas' argument that they were wrongly barred from responding to amendments Hospira Inc. made to an abbreviated new drug application to allegedly skirt infringement of patents on cardiac stress agent Lexiscan.
January 03, 2023
The Federal Circuit has shot down Gilead Sciences' and Astellas' argument that they were wrongly barred from responding to amendments Pfizer's Hospira Inc. unit made to an abbreviated new drug application to allegedly skirt infringement of patents on cardiac stress agent Lexiscan.
December 06, 2022
A Federal Circuit panel seemed skeptical Tuesday that Gilead Sciences and Astellas were wrongly barred from responding to amendments Hospira made "at the eleventh hour" to an abbreviated new drug application to skirt infringement of patents on cardiac stress agent Lexiscan.
December 01, 2022
A federal jury in Marshall, Texas, next week will hear long-simmering arguments from Apple that Ericsson isn't licensing its assortment of cellular patents considered essential to 4G and 5G standards at fair, reasonable and non-discriminatory rates.
November 30, 2022
As the year winds down, circuit courts will hear argument on the kinds of crimes Jan. 6 rioters can be charged with, whether federal law unconstitutionally delegates power to a private entity, and whether a class can be certified even if some class members weren't actually injured.
October 31, 2022
The Federal Circuit told Gilead that the drugmaker will now have to post a bond of more than $14 million to keep a temporary injunction in place blocking Pfizer from launching a generic version of the coronary artery test Lexiscan if the company wants to keep the rival test off the market until oral arguments kick off in Gilead's appeal this December.
September 27, 2022
The Federal Circuit imposed a temporary stay Tuesday that blocks Pfizer from launching a generic version of the coronary artery test Lexiscan, even though a Delaware federal judge ruled earlier this year that the new drug wouldn't actually infringe any patents Gilead has on Lexiscan.